Yan Zhu, MD — independent clinical due diligence pre-close, clinical-commercial architecture post-close. For funds and family offices in longevity, preventive health, and advanced aesthetics.
Financial and legal diligence are structurally blind to clinical risk.
Six-dimension clinical due diligence for consumer healthcare investments — before the term sheet.
See the framework →Most health products fail on architecture, not science.
Clinical-commercial rebuild for portfolio companies that closed before the operation could actually run.
See how it's built →Six dimensions. One question: does the clinical story hold up before you sign.
Degrees, registration, track record. Verified, not assumed.
What the pitch says versus what's actually true, right now.
Evidence behind the claimed outcomes, or the absence of it.
Clean cap table, undisclosed disputes, regulatory grey zones.
What's promised, against what the team can actually cover.
How much of the valuation walks out the door with one person.
Looking back at a high-profile 2024 collapse in the longevity clinic space, most people attribute it to the macro environment or a capital crunch. From a due diligence perspective, it died from a blind spot the venture world has long ignored: the total absence of Clinical Due Diligence.
Longevity clinics and premium aesthetics have historically raised capital on macro-narratives. Investors habitually ran Financial DD and Legal DD — but healthcare is not a pure traffic business; it has hard-core underlying clinical logic that neither discipline is built to test.
Run through the six dimensions, this particular collapse fails most visibly at Dimension 5 — Promise Scope – Delivery Architecture Fit. The rule is simple: how big the story is told dictates how hard-core the delivery architecture has to be.
The promise: a one-stop "aging deceleration" management platform, covering sleep, skin health, hormone optimization, and mental wellbeing — a textbook "assessment → intervention → tracking" closed loop, straight out of a business school case study.
The architecture behind it: a core medical team anchored by a single CMO with an internal medicine background — no dermatologist, no neurologist, no endocrinologist, not even on the external advisory bench. Four cross-disciplinary domains — neurology, dermatology, endocrinology, psychiatry — promised simultaneously, covered by none of them.
The sub-track is still flooded with concierge-style longevity clinics carrying the exact same fault line. Founders keep changing the story's packaging; the underlying delivery problem never gets solved.
Before financing the next longevity clinic: don't just read the financials and the compliance file. Ask what it scores on the Clinical Credibility Index — and whether the delivery architecture can actually cash the checks the narrative writes.
One question: can the operation you now own actually run — and be paid for twice.
Service lines across longevity, preventive health and aesthetics — delivered through a clinic, a device, a formulation, or a protocol. What can be delivered, what must never be claimed, which indications carry revenue.
Indications, contraindications, sequencing, intervals, expected response. Written for a doctor — or an operator — who has never met you.
Role design, competency sign-off, curriculum — for clinicians, injectors, or device operators. Consistency is the asset; individual talent is the risk.
Cost to deliver, modelled per unit — chair time and consumables for a clinic, COGS and shelf life for a supplement, per-treatment device cost and training overhead for an injectable or device line. Priced from the model, not copied from a competitor.
SOPs, audit schedule, escalation paths. The engagement is designed to end.
Twenty years treating the patients these products are built for. I know which promised outcomes hold up.
Clinical operations built from zero — hospital departments, my own private clinic, service lines around devices and injectables. Licensing, protocols, staffing, P&L.
Senior APAC roles at US medical device companies. I have seen why clinically sound products still fail to sell.
Most people hold one. This work is only possible at the intersection.
Reply within two business days — including if this is the wrong engagement.